Nasdaq · Healthcare
UNITED THERAPEUTICS Corp (UTHR)
As-reported financials and recent SEC filings for UNITED THERAPEUTICS Corp, latest fiscal period FY2025. Every figure is pulled straight from the company’s EDGAR filings — no estimates.
Snapshot
Revenue
$3.18B
Net income
$1.33B
Net margin
41.9%
Diluted EPS
$27.86
ROE
18.8%
P/E (TTM)
20.1×
Market cap
$23.03B
Debt / equity
—
Income statement (as reported)
| Line | FY2025 | FY2024 | FY2023 | FY2023 | FY2023 |
|---|---|---|---|---|---|
| Revenue | $3.18B | $2.88B | $2.33B | $1.94B | $1.69B |
| Gross profit | $2.80B | $2.57B | $2.07B | — | — |
| Operating income | $1.49B | $1.38B | $1.18B | $979.7M | $555.9M |
| Net income | $1.33B | $1.20B | $984.8M | $727.3M | $475.8M |
| Diluted EPS | $27.86 | $24.64 | $19.81 | $15.00 | $10.06 |
Source: company XBRL financial statements on SEC EDGAR.
Recent SEC filings
42026-06-26
View on EDGAR →42026-06-25
View on EDGAR →42026-06-24
View on EDGAR →42026-06-24
View on EDGAR →42026-06-23
View on EDGAR →42026-06-22
View on EDGAR →42026-06-22
View on EDGAR →1442026-06-18
View on EDGAR →Go deeper on UTHR
Search UNITED THERAPEUTICS Corp’s filings with cited answers, compare it against peers, build an operating model, and track it in your portfolio — all in one place.
Start freeData sourced from SEC EDGAR (public domain). Figures are as-reported and may be unaudited or restated; verify against the source filing before relying on them. Informational only — not investment advice.